PGC-1α-Mediated Mitochondrial Quality Control: Molecular Mechanisms and Implications for Heart Failure
L Chen, Y Qin, B Liu, M Gao, A Li, X Li… - Frontiers in cell and …, 2022 - frontiersin.org
Mitochondria with structural and functional integrity are essential for maintaining
mitochondrial function and cardiac homeostasis. It is involved in the pathogenesis of many …
mitochondrial function and cardiac homeostasis. It is involved in the pathogenesis of many …
Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) family in physiological and pathophysiological process and diseases
L Qian, Y Zhu, C Deng, Z Liang, J Chen… - … and Targeted Therapy, 2024 - nature.com
Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) family (PGC-1s),
consisting of three members encompassing PGC-1α, PGC-1β, and PGC-1-related …
consisting of three members encompassing PGC-1α, PGC-1β, and PGC-1-related …
Multiple levels of PGC-1α dysregulation in heart failure
S Oka, AD Sabry, KM Cawley… - Frontiers in Cardiovascular …, 2020 - frontiersin.org
Metabolic adaption is crucial for the heart to sustain its contractile activity under various
physiological and pathological conditions. At the molecular level, the changes in energy …
physiological and pathological conditions. At the molecular level, the changes in energy …
SMYD1a protects the heart from ischemic injury by regulating OPA1-mediated cristae remodeling and supercomplex formation
SMYD1, a striated muscle-specific lysine methyltransferase, was originally shown to play a
key role in embryonic cardiac development but more recently we demonstrated that loss of …
key role in embryonic cardiac development but more recently we demonstrated that loss of …
Estrogen signaling as a bridge between the nucleus and mitochondria in cardiovascular diseases
E Guajardo-Correa, JF Silva-Agüero, X Calle… - Frontiers in Cell and …, 2022 - frontiersin.org
Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality worldwide.
Epidemiological studies indicate that pre-menopausal women are more protected against …
Epidemiological studies indicate that pre-menopausal women are more protected against …
Novel therapeutic approaches enhance PGC1-alpha to reduce oxidant stress-inflammatory signaling and improve functional recovery in hibernating myocardium
R Aggarwal, KN Potel, EO McFalls, TA Butterick… - Antioxidants, 2022 - mdpi.com
Ischemic heart disease affects millions of people around the world. Current treatment
options, including coronary artery bypass grafting, do not result in full functional recovery …
options, including coronary artery bypass grafting, do not result in full functional recovery …
PERM1 regulates energy metabolism in the heart via ERRα/PGC−1α axis
S Oka, K Sreedevi, TS Shankar, S Yedla… - Frontiers in …, 2022 - frontiersin.org
Aims PERM1 is a striated muscle-specific regulator of mitochondrial bioenergetics. We
previously demonstrated that PERM1 is downregulated in the failing heart and that PERM1 …
previously demonstrated that PERM1 is downregulated in the failing heart and that PERM1 …
Improving mitochondrial function in preclinical models of heart failure: therapeutic targets for future clinical therapies?
A Gorący, J Rosik, J Szostak, B Szostak… - Expert Opinion on …, 2023 - Taylor & Francis
Introduction Heart failure is a complex clinical syndrome resulting from the unsuccessful
compensation of symptoms of myocardial damage. Mitochondrial dysfunction is a process …
compensation of symptoms of myocardial damage. Mitochondrial dysfunction is a process …
Perm1 regulates cardiac energetics as a downstream target of the histone methyltransferase Smyd1
S Oka, AD Sabry, AK Horiuchi, KM Cawley, SA O'Very… - PLoS …, 2020 - journals.plos.org
The transcriptional regulatory machinery in mitochondrial bioenergetics is complex and is
still not completely understood. We previously demonstrated that the histone …
still not completely understood. We previously demonstrated that the histone …
[HTML][HTML] Citri reticulatae Pericarpium attenuates Ang II-induced pathological cardiac hypertrophy via upregulating peroxisome proliferator-activated receptors gamma
G Ni, K Wang, Y Zhou, X Wu, J Wang… - Annals of …, 2020 - ncbi.nlm.nih.gov
Background Pathological cardiac hypertrophy is a major risk factor for cardiovascular
diseases, including heart failure. However, limited pharmacological therapies are available …
diseases, including heart failure. However, limited pharmacological therapies are available …